Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study

Park-Wyllie, Laura; Mamdani, Muhammad; Li, Ping; Gill, Sudeep S.; Laupacis, Andreas; Juurlink, David N.

doi:10.1371/journal.pmed.1000157

Cited by 111 publications

(87 citation statements)

References 32 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15,16 Ontario is Canada's most populous province, with a population of 13.6 million of whom approximately 2.1 million are aged 65 years or older. 17 These residents have universal access to hospital care, physicians' services, and prescription-drug coverage.…”

Section: Setting and Sources Of Datamentioning

confidence: 99%

Ticagrelor and bradycardia: a nested case–control study

Turgeon

Fernandes

Juurlink

et al. 2015

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

Section: Setting and Sources Of Datamentioning

confidence: 99%

Ticagrelor and bradycardia: a nested case–control study

Turgeon

Fernandes

Juurlink

et al. 2015

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…There is considerable uncertainty about when dementia pharmacotherapy should be discontinued because of a perceived lack of clinically meaningful benefit, and limited data on how long therapy with these agents should persist. [95][96][97][98] There are concerns that treatment may continue even when potentially inappropriate (for example, among patients on ChEIs hospitalized for bradycardia), 99 but also the possibility for underuse among eligible patients. 44 Decisions about continuing therapy need to be patient-centred, and based on clinical judgment rather than arbitrarily made.…”

Section: Appropriateness Of Discontinuationmentioning

confidence: 99%

Persistence and Adherence with Dementia Pharmacotherapy: Relevance of Patient, Provider, and System Factors

et al. 2014

View full text Add to dashboard Cite

This paper provides a comprehensive review of studies examining adherence and (or) persistence with dementia pharmacotherapy during the past decade, including a summary of the key patient-, drug-, system-, and provider-level factors associated with these measures. Estimates of adherence and 1-year persistence to these drugs have ranged from 34% to 94% and 35% to 60%, respectively. Though many studies reported nonsignificant associations, there are data suggesting that patient age, sex, ethnoracial background, socioeconomic status, and region-specific reimbursement criteria, as well as the extent and quality of interactions among patients, caregivers, and providers, may influence persistence with pharmacotherapy. As many studies relied on administrative data, limited information was available regarding the relevance of patient's cognitive and functional status or the importance of caregiver involvement or assistive devices to adherence or persistence. W W WPersistance et observance de la pharmacothérapie de la démence : pertinence des facteurs liés au patient, au fournisseur, et au système Cet article offre une revue détaillée des études examinant l'observance et (ou) la persistance de la pharmacothérapie de la démence au cours des dix dernières années, dont un résumé des principaux facteurs au niveau du patient, du médicament, du système et du fournisseur qui sont associés à ces mesures. Les estimations de l'observance et de la persistance d'un an à ces médicaments allaient de 34 % à 94 % et de 35 % à 60 %, respectivement. Même si de nombreuses études faisaient état d'associations non significatives, des données suggèrent que l'âge, le sexe, les origines ethnoraciales, le statut économique des patients et leurs critères de remboursement régionaux, ainsi que l'étendue et la qualité des interactions entre patients, soignants, et fournisseurs peuvent influencer la persistance de la pharmacothérapie. Comme bon nombre d'études s'appuyaient sur des données administratives, l'information disponible était limitée en ce qui concerne la pertinence de l'état cognitif et fonctionnel du patient, ou l'importance de l'implication du soignant ou des dispositifs d'assistance à l'observance ou à la persistance. In 2008, the estimated number of people with dementia in Canada was nearly half a million.2 Ensuring appropriate pharmacotherapy is an important component of care for people with dementia.3,4 ChEIs (for example, donepezil, rivastigmine, and galantamine) and the N-methyl-daspartate receptor antagonist memantine are approved for the symptomatic treatment of AD. 3,4 Recommendations made at the fourth CCCDTD (in 2012) included offering all people with AD a trial of a ChEI unless there are contraindications, using these agents for Parkinson disease dementia, and considering memantine for AD at a moderateto-severe stage. 5Investigating adherence and persistence with dementia pharmacotherapy is important in understanding both the therapeutic benefits and the cost-effectiveness of these medications. As symptomatic therapies, trea...

show abstract

“…Subtrochanteric fractures can be seen in patients on long-term use of bisphosphonates. 8 Our patient was on bisphosphonate only briefly, after his left femur fracture; thus, bisphosphonate use was unlikely to have affected the site of the fractures. The rapid bone loss in this patient was also remarkable.…”

Section: Discussionmentioning

confidence: 82%

Novel syndrome of four-limb proximal fragility fractures associated with HIV infection, cholestatic liver failure, and histiocytic infiltration of bone marrow

Nissen

Balzer

et al. 2012

View full text Add to dashboard Cite

We report a syndrome of four-limb proximal fragility fractures associated with HIV infection, cholestatic liver failure, and histiocytic infiltration of bone marrow in a 40-year-old African American man. the patient presented with multiple fractures in the proximal humeri and femurs without osteopenia in the vertebrae. His right humerus appeared normal on chest X-ray film 3 years before presentation when he was first diagnosed with HIV infection and abnormal liver functions. At presentation, the patient had vitamin D deficiency, hypogonadism, and low IGF-1 levels, but did not have hyperparathyroidism. bone biopsy showed diffuse foamy histiocytic infiltration of bone marrow at all fracture sites without evidence of infectious or neoplastic processes. Exhaustive search did not identify any similar cases in the English literature. Our case likely represents a novel syndrome, the etiology of which is probably multifactorial and includes HIV infection, cholestatic liver failure, immobility, and endocrine abnormalities. the case further calls for the need for monitoring of bone health in patients with HIV infection or liver disease.

show abstract

Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study

Abstract: Laura Park-Wyllie and colleagues examined the health records of more than 1.4 million older adults and show that initiation of cholinesterase inhibitor therapy is associated with a more than doubling of the risk of hospitalization for bradycardia.

Cited by 111 publications

References 32 publications

Ticagrelor and bradycardia: a nested case–control study

Ticagrelor and bradycardia: a nested case–control study

Persistence and Adherence with Dementia Pharmacotherapy: Relevance of Patient, Provider, and System Factors

Novel syndrome of four-limb proximal fragility fractures associated with HIV infection, cholestatic liver failure, and histiocytic infiltration of bone marrow

Contact Info

Product

Resources

About